SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 18, 2008--Exelixis, Inc. (Nasdaq: EXEL) announced today that George A. Scangos,
PhD, President and Chief Executive Officer of Exelixis will present at
the 27th Annual JPMorgan Healthcare Conference at 8:00
a.m. PT / 11:00 a.m. ET on Tuesday, January 13, 2009. Dr. Scangos will
discuss the company's corporate strategy and development pipeline.
The presentation will be webcast and may be accessed in the Event
Calendar page under Investors on the Exelixis website at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to
the discovery and development of novel small molecule therapeutics for
the treatment of cancer and other serious diseases. The company is
leveraging its fully integrated drug discovery platform to fuel the
growth of its development pipeline, which is primarily focused on
cancer. Currently, Exelixis' broad product pipeline includes
investigational compounds in Phase III, Phase II and Phase I clinical
development. Exelixis has established strategic corporate alliances with
major pharmaceutical and biotechnology companies, including
Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Wyeth Pharmaceuticals
and Daiichi-Sankyo. For more information, please visit the company's
website at http://www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
CONTACT: Exelixis, Inc.
Investor Contact:
Charles Butler, 650-837-7277
Senior Director, Corporate Communications
cbutler@exelixis.com
Media Contact:
Soleil Maxwell Harrison, 650-837-7012
Senior Manager, Corporate Communications
sharriso@exelixis.com
Source: Exelixis, Inc.
